BCL-X L PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS G12C -mutated cancers.
Autor: | Khan S; Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA. khansajid@cop.ufl.edu., Wiegand J; Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA., Zhang P; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA., Hu W; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA., Thummuri D; Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA., Budamagunta V; Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA.; Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, USA.; Genetics and Genomics Graduate Program, Genetics Institute, College of Medicine, University of Florida, Gainesville, FL, USA., Hua N; Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA., Jin L; Department of Anatomy and Cell Biology, College of Medicine, University of Florida, Gainesville, FL, USA., Allegra CJ; Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA., Kopetz SE; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zajac-Kaye M; Department of Anatomy and Cell Biology, College of Medicine, University of Florida, Gainesville, FL, USA., Kaye FJ; Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA., Zheng G; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA., Zhou D; Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, 32610, USA. zhoudaohong@cop.ufl.edu. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of hematology & oncology [J Hematol Oncol] 2022 Mar 09; Vol. 15 (1), pp. 23. Date of Electronic Publication: 2022 Mar 09. |
DOI: | 10.1186/s13045-022-01241-3 |
Abstrakt: | KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRAS G12C , was recently approved for the treatment of KRAS G12C -mutated non-small cell lung cancer (NSCLC). However, the efficacy of sotorasib and other KRAS G12C inhibitors is limited by intrinsic resistance in colorectal cancer (CRC) and by the rapid emergence of acquired resistance in all treated tumors. Therefore, there is an urgent need to develop novel combination therapies to overcome sotorasib resistance and to maximize its efficacy. We assessed the effect of sotorasib alone or in combination with DT2216 (a clinical-stage BCL-X (© 2022. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |